[{"orgOrder":0,"company":"Biotest","sponsor":"Biotest","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Human Hepatitis B Immunoglobulin","moa":"||Surface antigen (HBsAg)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Solution","sponsorNew":"Biotest \/ Biotest","highestDevelopmentStatusID":"8","companyTruncated":"Biotest \/ Biotest"},{"orgOrder":0,"company":"Biotest","sponsor":"Biotest","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cytofulvin","moa":"||Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biotest \/ Biotest","highestDevelopmentStatusID":"8","companyTruncated":"Biotest \/ Biotest"},{"orgOrder":0,"company":"Biotest","sponsor":"Biotest","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ganciclovir","moa":"||Human herpesvirus 1 DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotest \/ Biotest","highestDevelopmentStatusID":"8","companyTruncated":"Biotest \/ Biotest"}]

Find Clinical Drug Pipeline Developments & Deals by Biotest

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 12, 2022

                          Lead Product(s) : Ganciclovir,Foscarnet Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : University Hospital, Lille

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Hepatect

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 26, 2022

                          Lead Product(s) : Human Hepatitis B Immunoglobulin,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : Hannover Medical School

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Cytotect

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          June 22, 2021

                          Lead Product(s) : Cytofulvin,Inapplicable

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Recipient : University Hospital, Bordeaux

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Human Normal Immunoglobulin,Inapplicable

                          Therapeutic Area : Gastroenterology

                          Study Phase : Phase II

                          Recipient : RWTH Aachen University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          November 07, 2017

                          Lead Product(s) : Human Normal Immunoglobulin,Inapplicable

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Recipient : RWTH Aachen University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          July 12, 2012

                          Lead Product(s) : BT062,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Biotest

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank